Efficacy of Intermittent Low Dose Alendronate in Thai Postmenopausal Osteoporosis

Endocrine Research

Volumn 30, Issue 1, 2004, Pages 29-36

  Chailurkit, La Or ^a   Aunphongpuwanart, Srikorn ^a   Ongphiphadhanakul, Boonsong ^a   Jongjaroenprasert, Wallaya ^a   Sae Tung, Sunee ^a   Rajatanavin, Rajata ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Alendronate; Osteoporosis; Weekly dosing

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE;

ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL ARTICLE; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HUMAN; LOW DRUG DOSE; LUMBAR SPINE; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; THAILAND; TREATMENT OUTCOME; VERTEBRA BODY;

AGED; ALENDRONATE; BONE DENSITY; CALCIUM; COLLAGEN; COST SAVINGS; DENSITOMETRY, X-RAY; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; THAILAND;

EID: 1842534038     PISSN: 07435800     EISSN: None     Source Type: Journal    
DOI: 10.1081/ERC-120028385     Document Type: Article

References (23)

1. McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS, Fuleihan G El-H, Reda C, Yates AJ, Ravn P. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med 1998; 128(4):253-261.
2. Ravn P, Bidstrup M, Wasnich RD, Davis JW, McClung MR, Balske A, Coupland C, Sahota O, Kaur A, Daley M, Cizza G. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med 1999; 131(12):935-942.
3. Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P, McClung M, Balske A, Thompson D, Daley M, Yates AJ. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med 1998; 338(8):485-492.
4. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348(9041):1535-1541.
5. Karpf DB, Shapiro DR, Seeman E, Ensrud KE, Johnston CC Jr, Adami S, Harris ST, Santora AC II, Hirsch LJ, Oppenheimer L, Thompson D. Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA 1997; 277(14):1159-1164.
6. Watts N, Freedbolim D, Daifotis A. The clinical tolerability profile of alendronate. Int J Clin Pract 1999; 101(suppl):51-61.
7. Lin JH, Russell G, Gertz B. Pharmacokinetics of alendronate: an overview. Int J Clin Pract 1999; 100(suppl):18-26.
8. Khan SA, Kanis JA, Vasikaran S, Kline WF, Matuszewski BK, McCloskey EV, Beneton MN, Gertz BJ, Sciberras DG, Holland SD, Orgee J, Coombes GM, Rogers SR, Porras AG. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 1997; 12(10):1700-1707.
9. Greenspan SL, Bone G III, Schnitzer TJ, Watts NB, Adami S, Foldes AJ, Roux C, Levine MA, Uebelhart B, Santora AC II, Kaur A, Peverly CA, Orloff JJ, Rizzoli R. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002; 17(11):1988-1996.
10. Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC II, Kaur A, Thompson DE, Yates J, Orloff JJ. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000; 12(1):1-12.
11. Chailurkit L, Jongjaroenprasert W, Rungbunnapun S, Ongphiphadhanakul B, Sae-tung S, Rajatanavin R. Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis. J Bone Miner Metab 2003; 21(6):421-427.
12. Kung AW, Yeung SS, Chu LW. The efficacy and tolerability of alendronate in postmenopausal osteoporotic Chinese women: a randomized placebo-controlled study. Calcif Tissue Int 2000; 67(4):286-290.
13. Lau EM, Woo J, Chan YH, Griffith J. Alendronate prevents bone loss in Chinese women with osteoporosis. Bone 2000; 27(5):677-680.
14. Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ, Stych B. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study Group. Osteoporos Int 1999; 9(5):461-468.
15. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333(22):1437-1443.
16. Felsenberg D, Alenfeld F, Bock O, Hammermeister C, Gowan W. Placebo-controlled multicenter study of oral alendronate in postmenopausal osteoporotic women. FOSIT-Study-Group. Fosamax International Trial. Maturitas 1998; 31(1):35-44.
17. Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Taga M, Nakamura T, Kaneda K, Minaguchi H, Inoue T, Morii H, Tomita A, Yamamoto K, Nagata Y, Nakashima M, Orimo H. A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group. Osteoporos Int 1999; 10(3):183-192.
18. Chesnut CH III, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Singer FR, Stock JL, Yood RA, Delmas PD, Kher U, Pryor-Tillotson S, Santora AC II. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995; 99(2):144-152.
19. Devogelaer JP, Broll H, Correa-Rotter R, Cumming DC, De Deuxchaisnes CN, Geusens P, Hosking D, Jaeger P, Kaufman JM, Leite M, Leon J, Liberman U, Menkes CJ, Meunier PJ, Reid I, Rodriguez J, Romanowicz A, Seeman E, Vermeulen A, Hirsch LJ, Lombardi A, Plezia K, Santora AC, Yates AJ, Yuan W. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 1996; 18(2):141-150.
20. Adami S, Passeri M, Ortolani S, Broggini M, Carratelli L, Caruso I, Gandolini G, Gnessi L, Laurenzi M, Lombardi A, Norbiato G, Pryor-Tillotson S, Reda C, Romanini L, Subrizi D, Wei L, Yates AJ. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 1995; 17(4):383-390.
21. Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 1997; 7(4):390-406.
22. Parfitt AM. Morphologic basis of bone mineral measurements: transient and state effects of treatment in osteoporosis. Miner Electrolyte Metab 1980; 4:273-287.
23. Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales JA, Menkes CJ, Wasnich RD, Bone HG, Santora AC, Wu M, Desai R, Ross PD. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 2000; 85(9):3109-3115.